OCT 0 9 2009

PTO/SB/08 (2/92) 1 of 6 Sheet +

		Form PTO-14	149	Attorney's Docket No. ARR-0036 Applicant(s)		lication Seria	al No.
ME		N DIGG! 00!!	TRAHEM	ARK-0036	10/3	579,088	
INFO	ORMATIO	N DISCLOSU	RE STATEMENT	Applicant(s) Manzer D	Jurrani o	t al	
				i Walizel L	vurrani, c	it ai.	•
	•			Filing Date:	Gro	up Art Unit:	-
	(use sev	eral sheets if	necessary)	January 14, 2008	164	6	
			al alam i Carl	.S. PATENT DOCUMENTS			
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
-	1.	06/1988	4,752,576	Brake, et al.	8	8	
	2.	10/1988	4,775,622	Hitzeman, et al.,	100		
	3.	06/1989	4,837,148	Cregg			
-	4.	06/1989	4,839,283	Kawasaki, et al.,			
	5.	05/1990	4,929,555	Cregg, et al.		1	
	6.	07/1990	4,940,661	Etcheverry, et al.			
	7.	04/1991	5,010,003	Chang, et al.	9005000		
* **	8.	05/1991	5,013,652	Stausberg, et al.	. 8		
	9.	07/1999	5,922,569	Heim, et al.	1		
	10.	05/2000	6,068,994	Barr	80	l	
	11.	08/2000	6,103,500	Innis, et al.	9000		
	12.	03/2001	6,204,012	Hellmuth, et al.	100		
	13.	5/19/2002	5,114,953	Galardy, et al.	-	, i	
	14.	6/30/1998	5,773,438	Levy, et al.		000	
•	15.	12/9/1997	5,696,147	Galardy			
	16.	4/6/1999	5,892,112	Levy, et al.			
	17.	4/8/2003	6,544,497	Zhu, et al.		W	
	² 18.	02/17/2004	6,693,096	Fritz, et al.		A	
Exam.	19.	5/25/2004	6,740,655	Magee, et al.		000	
Initias	20.	10/26/1999	5,972,986	Seibert, et al.			
	21.	10/22/2002	6,469,040	Seibert, et al.			
	22.	10/17/2000	6,133,304	Peterson, Jr., et al.			
	23.	07/14/1998	5,780,440	Lezdey, et al.		-	
	24.	10/26/1993	5,256,657	Singh, et al.			
······································	25.	04/10/2003	2003/0068280	Bannister, et al.		999	
	26.	11/13/2003	2003/0211548	Packard, et al.	8	•	
	27.	07/25/2002	2002/0099013	Piccariello, et al.	90	•	
	28.	1/14/1997	5,594,106	Black, et al.			
	29.	04/24/2003	2003/0078276	Andrianjara, et al.	1		
	30.	04/17/2003	2003/0073217 A1	Barr, et al.		300	
<u>-</u>	31.		4,752,576	Brake, et al.		98908	
	32.	12/03/2002	6,489,308 B1	Shapiro, et al.		800000	
	33.	11/30/1999	5,993,783	Eljamal, et al.	1	90000	
							

EXAMINER:	DATE CONSIDERED:
· <u>.</u>	

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

0 , 5 .

PTO/SB/08 (2/92) 2 of 6 Sheet Total

Form PTO-1449			49	Attorney's Docket No. Application Serial No.				
•				ARR-0036 10/579,088				
INFC	RMATIO	N DISCLOSU	RE STATEMENT	Applicant(s)				
				Manzer Durrani, et al.				
<u> </u>				Filing Date:	Gro	up Art Unit:		
	(use sev	eral sheets if	necessary)	January 14, 2008	164	6		
**			FORE	IGN PATENT DOCUMENTS				
Examiner	Ref.	Date	Document No.	Name .	Class	Subclass	Translat	ion
Initials	No.			· · · · · · · · · · · · · · · · · · ·			YES	NO
	34.		WO 1984/04538	WO	-			
	35.	06/27/2002	WO 2002/50287	WO				
	36.	12/27/1990	EP 73,654 A	EP				
No Fee V	37.	09/28/1988	EP 0 284 044 A1	EP	900			
1 7	38.	06/27/2002	WO 02/50287	WO	0000			
1.	39.	10/17/1996	WO 96/32152	WO				
	40.	04/23/1998	WO 98/16205	WO	100			
	41.	09/21/2000	WO 00/54797	WO	000			
	42.	07/22/2004	WO 2004/060528	WO	ANDON			
	43.	07/31/2002	EP 0 648 838	EP	googge			
	44.	10/02/2002	EP 1 047 450	EP	gggggg	docarage		
	45.	07/31/2002	EP 1 226 136	EP	200200	oseog		
	46.	06/15/2000	WO 00/34237	WO	postori	8		
	47.	07/11/2002	WO 02/053138	WO	905000			
	48.	08/22/2002	WO 02/064080	WO	00000	8000		
	49.	08/21/2003	WO 03/068188	WO				
	50.	09/18/2003	WO 03/075959	WO				
	:51.	07/01/1999	WO 2004/103364	_WO		GO COLORDO		
	52.	01/13/2005	WO 2005/003150	WO				
	53.	06/11/1992	WO 92/09282	WO		00000		
	54.	06/11/1992	WO 92/09556	WO		100000		
	55.	06/11/1992	WO 92/09563	WO				
	56.	07/22/1993	WO 93/13741	WO		000000		
校	57.	02/03/1994	WO 94/02446	WO				
	58.	09/29/1994	WO 94/21625	WO				
u*	59.	10/13/1994	WO 94/22309	WO				
·	60.	04/13/1995	WO 95/09841	WO				
	61.	07/27/1995	WO 95/19965	WO		1000		
	62.	05/30/1996	WO 96/16027	WO		1		
	63.	11/13/1997	WO 97/42168	WO		30000		
	64.	2/26/1998	WO 98/07742	WO		-		
	65.	04/09/1997	WO 98/14424	WO		0000		
	66.	10/8/1998	WO 98/43946	WO		0		
	67.	10/29/1998	WO 98/47863	WO				
	68.		WO 99/44989	WO		1000		
	69.	07/01/1999	WO 99/32150	WO		9700000		
EVASABLES				DATE CONSIDERED.				

EXAMINER:	DATE CONSIDERED:
•	

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not inconformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

				21166(robosobook			
		Form PTO-1449	Attorney's Docket No.	Application Serial No.			
INITO		N DICCI OCUDE OTATEMENT	ARR-0036	10/579,088			
INFORMATION DISCLOSURE STATEMENT				Applicant(s) Manzer Durrani, et al.			
			"	nanzer Durram, et al.			
			Filing Date:	Group Art Unit:			
	(use sev	eral sheets if necessary)	January 14, 2008	1646			
		07/31/2002 EP 1 226 119	EP				
		(includi	OTHER DOCUMENTS ng author, title, date, pertinent pages,	etc.)			
Examiner	Ref.	Title					
Initials	No.						
	71.			cal Chemistry, 257(6): 3026-3031, 1982.			
	72.	Technology," 29: 611-620, 2001	l	hibitor Alpha-1-Antitrypsin, Enzyme and Microbial			
	73.	258(4): 2674-2682, 1983.		nase II Gene," The Journal of Biological Chemistry,			
	74.	Barr, et al., "Yeast Genetic Eng	ineering," Chap. 6, Butterworths, 1989) .			
	75.	Broach, et al., "Transformation Gene, 8:121-133, 1979.	in Yeast: Development of a Hybrid Clo	oning Vector and Isolation of the CAN1 Gene,"			
Pearson, et al., "Improved Tools for Biological Sequence Comparison," Proceedings of the National Academ 76. Science, 85: 244-2448, 1988.				n," Proceedings of the National Academy of			
	77.	Tuite, M.F., et al., "Regulated H EMBO Journal, <u>1(5)</u> : 603-608, 1		terferon-Alpha in Saccharomyces cerevisiae," The			
	Kurachi, K., et al., "Cloning and Sequence ofcDNA Coding for α ₁ -Antitrypsin," Proc Natl Acad Sci USA, Bio 78(11): 6826-6830, 1981.						
	79.	Kurjan, J., et al., "Structure of a Copies of Mature α-Factor," Ce		utative α-Factor Precursor Contains Four Tandem			
; ;	80.			are of TRP1 R1 Circle, a Multiple-Copy Synthetic ", Molecular and Cellular Biology, <u>2(3)</u> : 221-232,			
	81.	Dayhoff, et al., "A Model of Evo Biomedical Research Foundation		f Protein Sequence and Structure, National			
	82.	Hein, J "Unified Approach to A	Alignment and Phylogenies," Methods	in Enzymology, <u>183</u> : 626-645, 1990.			
Higgins, D.G., et al., "Fast and Sen: Communications, <u>5(2)</u> : 151-153, 19							
	84.	Jones, E.W., "Vacuolar Proteas	es in Yeast Saccharomyces Cerevisia	e," Methods in Enzymology, 85(31):372-386, 1990.			
	85.	Kurtz, M.B., et al., "Integrative T and Cellular Biology, <u>6(1)</u> : 142-		sing a Cloned Candida ADE2 Gene," Molecular			
EXAMINE	₹:		DATE CONSIDERE	D:			

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation con	forms with MPEP 609. Draw a line through the citation if not in

conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

		Form PTO-1449	Attorney's Docket No. ARR-0036	Application Serial No. 10/579,088	
INF	ORMATIO	N DISCLOSURE STATEMENT	Applicant(s)	10/0/0,000	
			Manzer Durrani, et al.		
	<u> </u>		Filing Date:	Group Art Unit:	
	(use seve	eral sheets if necessary)	January 14, 2008	1646	
	86.	of Basic Microbiology, <u>25(2)</u> : 141-14		andida maltosa and Pichia guilliermondii," Journal	
	87.	Myers, E.W., et al. "Optimal Alignm	• •		
	88.	Robinson, D.F., "Comparison of La 119,1971.	beled Trees with Valency Three,"	Journal of Combinational Theory, <u>11</u> : 105-	
	89.	Saitou, N., et al., "The Neighbor-Joi Biology and Evolution, pp. 406-425		Reconstructing Phylogenetic Trees," Molecular	
	90.	Wilbur, W.J., et al., "Rapid Similarit 726-730, 1983.	y Searches of Nucliec Acid and P	rotein Data Banks," Proc Natl Acad of Sci USA, <u>80</u> :	
	91.	Zou, et al., "Maspin, a Serpin with T 529, 1994.	umor-Suppressing Activity in Hu	man Mamary Epithelial Cells," Science, <u>263</u> : 526-	
	Gleeson, M.A., et al., "Transformation of the Methylotrophic Yeast Hansenula polymorpha," Journal of General 92. Microbiology, <u>132</u> : 3459-3465, 1986.				
	93.	Roggenkamp, R., et al., "Transform Replication and Integration Vectors		Hansenula polymorpha by Autonomous 1986.	
	94.	Das, et al., "Transformation of Kluy	veromyces Fragilis," Journal of E	acteriology, <u>158(3)</u> : 1165-1167, 1984.	
	95.	De Louvencourt, et al., "Transforma 154(2): 737-742, 1983.	ation of Kluyveromyces lactic by	Killer Plasmid DNA," Journal of Bacteriology,	
	96.	Van Den Berg, et al., "Kluyveromyc of Prochymosin", Biotechnology, <u>8</u>		ne Expression: Expression and Secretion	
	97.	Cregg, et al., "Pichia Pastoris as a l 1985.	lost System for Transformations	" Molecular and Cellular Biology, <u>5(12)</u> : 3376-3385,	
	98.	Hinnen, A., et al., "Transformation of	of Yeast," Proc. Natl. Acad of Sci.	USA, Genetics, <u>75(4)</u> : 1929-1933, 1978.	
	99.	Ito, H., et al., "Transformation of Int 168, 1983.	act Yeast Cells Treated with Alka	i Cations", Journal of Bacteriology, <u>153(1)</u> : 163-	
	100.	_		via lipolytica," Current Genetics, <u>10</u> : 39-48, 1985.	
	101.	-		polytica," Current Genetics, <u>10</u> : 49-58, 1985.	
102. Winkler, M., "Time-Profiling and Env			viromental Design in Computer - C	controlled Fermentation and Enzyme Production,"	

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conf	orms with MPEP 609. Draw a line through the citation if not in

conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449			Attorney's Docket No.	Application Serial No.	
1815		LDIGGLOGIUSE OTATEMENT	ARR-0036	10/579,088	
INF	DRMATION	N DISCLOSURE STATEMENT	Applicant(s)		
			1	lanzer Durrani, et al.	
			Filing Date:	Group Art Unit:	
	(use seve	eral sheets if necessary)	January 14, 2008	1646	
		96-184, 1991.	-	n Control, Ellis Horwood Limited, Chp. 4 and 5, pp.	
Schiestl, et al., "High Efficiency Train 103. Current Genetics, 16: 339-346, 1989.			formation of Intact Yeast Cells I	Jsing Single Stranded Nucleic Acids as a Carrier,"	
	104.	Jones, E.W., "Tackling the Protease P 1991.	Problem in Saccharomyces Cere	visiae," Methods in Enzymology, <u>194</u> : 428-453,	
;	105.	du Preez, J.C., et al., "Transcriptional Recombinant Strains of Saccharomy			
	106.	European Search Report dated Janua	ry 9, 2007.		
	107.			a Malaria Transmission-Blocking Vaccine A Agarose," Nature Publishing Group, <u>12</u> : 494-499,	
	108.		fanufacturing of a Malaria Trans	nant Proteins in Yeast Under the ADH2 Promoter: mission Blocking Vaccine Candidate," Journal of	
	O'Connor, G.M., "Design and Evaluation of Control Strategies for High Cell Density Fermentations," Bio Bioengineering, 39 (3):293-304, 1992.				
	110.	Sabin, E.A., et al., "High-Level Expres Saccharomyces Cervisiae," Bio/Tech		Chimeric Ubiquitin Fusion Proteins in	
Amiali, et al., "High Nisin Z Producti of Microbiology & Biotechnology, 14			•	in Whey Permeate with Aeration," World Journal	
÷.	112.	Alpha-1-Antichymotrypsin," J. Biol. C	hem., 255(9): 3931-3934, 1980.	ve and Oxidized Alpha-1-Proteinase Inhibitor and	
	113.	Plenum Press, NY, Chap. 9 pp. 263-28	5, 1993.	Orugs: Case Histories," Wang and Pearlman,	
	114.	Alpha1-Antitrypsin Formulations," PD	A Journal of Pharmaceutical Sc	on, and Storage of Lyophilized Recombinant ience and Technology, 48(5): 241-246, 1994.	
	115.	the Mouse," COPD: Journal of Chroni	c Obstructive Pulmonary Diseas		
	116.	An Integrated Analysis," European Re	espiratory Society, Abstract, 200		
	117.	2007.	•	estigation," Respiratory Medicine, 101: 1924-1930,	
	118.	<u>128(1)</u> : 199-203, 1985.		heterogeneity,"Biochem. Biophys. Res. Comm.,	
	119.	Schasteen, C.S., et al., "Synthetic Pep	tide Inhibitors of Complement S	erine Proteases - Significant Increase in Inhibitor	

EXAMINER:	DATE CONSIDERED:					
	`					
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.						
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).						

6 of 6 Sheet (2/92)

Form PTO-1449			Attorney's Docket No. ARR-0036	Application Serial No. 10/579,088	
INFO	RMATION	I DISCLOSURE STATEMENT	Applicant(s)		
		•		Manzer Durrani, et al.	
			Filing Date:	Group Art Unit:	
	(use seve	ral sheets if necessary)	January 14, 2008	1646	
		Potency Provides Further Support for 479, 1991.	the Functional Equivalence H	ypothesis," Molecular Immunology, 28(1/2): 472-	
	120.	Churg, et al., "Proteases and Emphys	ema," Current Opinion in Puln	nonary Medicine, <u>11</u> : 153-159, 2005.	
·	121.	Huang, et al., "Expression and Purifice Biotechology Prog, 17: 126-33, 2001.	cation of Functional Human Alpha1-Antitrypsin from Cultured Plant Cells,"		
	122.	Rabe, "Outcome Measures in COPD,"	" Primary Care Respiratory Journal, 13: 177-178, 2004.		
	123.	Rosenerg, et al., "Synthesis in Yeast of 312: 77-80, 1984.	of a Functional Oxidation-Resi	stant Mutant of Human Alpha1-Antitrypsin," <i>Nature</i> ,	
	124.	Medicine, 21(4):621-632, 2000.		ructive Pulmonary Disease," Clinics in Chest	
	125.	Travis, et al., "Isolation and Properties Journal of Biological Cheimstry, 260(7		ed Variants of Human Alpha1-Proteinase Inhibitor,"	
	126.	Terashima, et al., "Production of Fund Biotechnol., <u>52</u> : 516-523, 1999.	tional Human Alpha1-Antitryp	sin by Plant Cell Culture," <i>Appl. Microbiol.</i>	
	127.	Barnes, P.J., "Novel Approaches and <i>Crit. Care Med.</i> , <u>160</u> :S72-S79, 1999.	Targets for Treatment of Chro	nic Obstructive Pulmonary Disease," Am.J. Respir.	
	128.	Roche, N., et al., "Current Issues in th 229, 1997.	e Management of Chronic Obs	structive Pulmonary Diseases," Respirology, <u>2</u> : 215-	
	129.	He, J.Q., et al., "Pharmacogenomics o			
	130.		ohil-Elastase Defenses of the Lower Respiratory Tract in Alpha 1-Antitrypsin h an Aerosol of Alpha 1-Antitrypsin," Annals of Internal Medicine, 111(3): 206-212,		

EXAMINER:	/Claire Kaufman/	DATE CONSIDERED: 06/25/2010
EXAMINER:	Initial if citation considered, whether or not the citation conf	forms with MPEP 609. Draw a line through the citation if not in

conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).